Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Dare Bioscience, Inc.
Daré Bioscience will hold a special meeting of stockholders on November 10, 2026, to approve the potential future issuance of common stock upon the exercise of outstanding warrants in accordance with Nasdaq listing rules. The meeting, based on the record date of September 30, 2026, will also address the adjournment of the meeting if necessary to solicit additional proxies.…more
Dare Bioscience, Inc.
Daré Bioscience has received a notification from Nasdaq stating that its common stock failed to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until March 29, 2027, to regain compliance with this requirement and is currently evaluating options to address the deficiency.…more
Dare Bioscience, Inc.
Daré Bioscience released its latest corporate presentation on October 1, 2026. The company intends to utilize these materials in meetings with securities market participants, and the presentation is available on the company's investor relations website.…more
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
Daré Bioscience Sponsors Menopause Management Educational Program
Daré Bioscience is sponsoring a medical education program focused on managing menopause after breast cancer to highlight its non-hormonal treatment research. This initiative is part of the company's academic outreach and does not represent a material financial or regulatory milestone.…more
●●●●●●●● ●●●●● ●●●●●●
Daré Bioscience has launched a new video series titled 'CEO Corner' to provide investors with insights into its women's health product portfolio and corporate strategy. The initiative aims to enhance transparency and communicate the company's business priorities directly to shareholders.…more
●●●●●●●● ●●●●● ●●●●●●
Daré Bioscience announced it will present Phase 1 clinical data for its topical Sildenafil Cream at the upcoming SMSNA annual meeting. The study highlights the product's lower systemic exposure compared to oral sildenafil, supporting its ongoing development as a treatment for female sexual arousal disorder.…more
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.